Treatment for Canine Hemangiosarcoma (HSA) of the Spleen

Treatment for canine hemangiosarcoma (HSA) of the spleen.

Study details.

Qualified patients in this fully-funded study (all diagnostics, treatment, and exams) will receive 4 doses of Paccal Vet® chemotherapy and will be monitored for up to 12 months following spleen removal.

Inclusion criteria:

Dogs diagnosed with stage I or stage II splenic HSA, and some qualifying stage III

Eligible to receive first dose of Paccal Vet therapy within 30 days of spleen removal

Owner consent to enrollment in the study and ability to comply with the protocol visit schedule

Exclusion criteria:

Dogs that have previously received chemotherapy

Dogs that have an active systemic infection

Any other disease state that requires medications prohibited by the study

Dogs that are pregnant, lactating, or intended for breeding during the study period

Dogs currently enrolled in another therapeutic clinical study

No clinically significant abnormalities on lab work

Known Multidrug Resistant 1 gene (MDR1) mutation (mut/wt or mut/mut)

For any dog considered by the Investigator to be at high risk of carrying an MDR1 mutation (e.g. Standard Collie, Long-haired Whippet, or Australian Shepherd [standard and miniature]), MDR1 testing will be performed prior to enrollment. If an MDR1 mutation is detected, the patient will be excluded

Any other reason which, according to the Investigator, would affect the safety of the dog or severely interfere with study procedures

Locations and contacts:

Duration of study.

Patient participation will be up to 12 months. The study will be active until 2026.

Covered costs.

All study-related costs are covered by the sponsor.

Treatment for Canine Hemangiosarcoma (HSA) of the Spleen